Tango Therapeutics, Inc.
TNGX
Rang în acțiuni
#4497
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Preț acțiune
$27.18
Ultima sincronizare: 2026-07-31
Capitalizare de piață
$3.38B
Schimbare (1 zi)
-1.41%
Schimbare (1 an)
213.86%
Țară
US
Tranzacționează Tango Therapeutics, Inc. (TNGX)
Categorie
Healthcare
Istoric al prețului acțiunii pentru Tango Therapeutics, Inc. (TNGX)
Cel mai mare preț de închidere: $28.53 pe 2026-07-01
Cel mai mic preț de închidere: $10.21 pe 2020-09-01
Cel mai mic preț de închidere: $10.21 pe 2020-09-01
Istoric al prețului acțiunii pentru Tango Therapeutics, Inc. din 2020 până în 2026
Evoluția anuală a prețului acțiunii
| An | Performanță |
|---|---|
| 2026 (TTM) | 94.33% |
| 2025 | 186.22% |
| 2024 | -66.61% |
| 2023 | 25.09% |
| 2022 | -28.88% |
| 2021 | -3.27% |
| 2020 | 0.00% |
Prețul acțiunii pentru companii similare sau concurente
| Companie | Preț acțiune | Variație 1an% | Țara |
|---|---|---|---|
| $535.55 | 25.59% |
US
|
|
| $187.49 | 598.30% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $876.18 | 7.62% |
NL
|
